|Application ||WB, IHC-F, IF, FC, E, IP|
|Calculated MW||88415 Da|
|Purification||Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant|
|Immunogen||Purified human beta1 integrin preparation from HT1080 fibrosarcoma cell extract.|
|Shelf Life||18 months from date of despatch.|
|Other Names||Integrin beta-1, Fibronectin receptor subunit beta, Glycoprotein IIa, GPIIA, VLA-4 subunit beta, CD29, ITGB1, FNRB, MDF2, MSK12|
|Target/Specificity||Mouse anti-Human CD29 monoclonal antibody, clone 12G10 recognizes human CD29 also known as beta1 integrin or VLA-4 subunit alpha. CD29 is a ~130 kDa under reducing, ~115 kDa under non-reducing conditions single pass type I transmembrane glycoprotein. CD29 acts as the common beta subunit of the heterodimeric very late antigens 1-6, complexing with CD49a-f respectively where it forms part of the receptors for laminin , collagen and fibronectin. the VLA heterodimers ediate cell-cell and cell-matrix interactions.Mouse anti-human CD29, clone 12G10 binding to cells adhering via VLA-4 results in actin cytoskeletal disruption and subsequent inhibition of attachment and spreading whilst 12G10 binding to cells adhering via VLA-5 results in enhancement of both these processes (Humphrieset al.2005). Clone 12G10 enhances alpha 5 beta 1-fibronectin interactions and binds to a region of CD25 containing the binding epitopes of several other anti-CD29 antibody clones. However, unlike these, binding of 12G10 is enhanced in the presence of ligands such as fibronectin fragments (Mouldet al.1995). Binding of antibody clone 12G10 to the integrin β1 subunit is affected by divalent cations and the binding epitiope appears to be located around residues 207-218 in the b1 subunit putative A-domain (Mouldet al.1998)|
|Preservative & Stabilisers||0.09% Sodium Azide|
|Storage||Store at +4℃ or at -20 ℃.|
|Precautions||Anti-Human CD29 Antibody, clone 12G10 is for research use only and not for use in diagnostic or therapeutic procedures.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
1. Sodek, K.L. et al. (2009) Compact spheroid formation by ovarian cancer cells is associated with contractile behavior and an invasive phenotype.Int J Cancer. 124: 2060-70. 2. Mould, A.P. et al. (1995) Regulation of integrin alpha 5 beta 1 function by anti-integrin antibodies and divalent cations.Biochem Soc Trans. 23 (3): 395S. 3. Mould, A.P. et al. (1995) Identification of a novel anti-integrin monoclonal antibody that recognises a ligand-induced binding site epitope on the beta 1 subunit.FEBS Lett. 363 (1-2): 118-22. 4. Matthews,B.D. et al. (2010) Ultra-rapid activation of TRPV4 ion channels by mechanical forces applied to cell surface [beta]1 integrins.Integr Biol (Camb). 2: 435-42. 5. Aasted, B. et al. (2007) Reactivity of monoclonal antibodies to human CD antigens with cells from mink.Vet Immunol Immunopathol. 119: 27-37. 6. Kawaguchi, N. et al. (2003) ADAM12 induces actin cytoskeleton and extracellular matrix reorganization during early adipocyte differentiation by regulating beta1 integrin function.J Cell Sci. 116: 3893-904. 7. Loughran, G. et al. (2005) Mystique is a new insulin-like growth factor-I-regulated PDZ-LIM domain protein that promotes cell attachment and migration and suppresses Anchorage-independent growth.Mol Biol Cell. 2005 Apr;16(4):1811-22. 8. Werner, J. et al. (2012) Expression of integrins and Toll-like receptors in cervical cancer: Effect of infectious agents.Innate Immun. 18: 55-69. 9. Iba, K. et al. (2000) The cysteine-rich domain of human ADAM 12 supports cell adhesion through syndecans and triggers signaling events that lead to beta1 integrin-dependent cell spreading.J Cell Biol. 149: 1143-56. 10. Meng, X. et al. (2005) Evidence for the presence of a low-mass beta1 integrin on the cell surface.J Cell Sci. 118: 4009-16. 11. Whittard, J.D. and Akiyama, S.K. (2001) Positive regulation of cell-cell and cell-substrate adhesion by protein kinase A.J Cell Sci. 114: 3265-72. 12. Rodriguez-Teja, M. et al. (2015) AGE-modified basement membrane cooperates with Endo180 to promote epithelial cell invasiveness and decrease prostate cancer survival.J Pathol. 235 (4): 581-92. 13. Zhong, C. et al. (1998) Rho-mediated contractility exposes a cryptic site in fibronectin and induces fibronectin matrix assembly.J Cell Biol. 141: 539-51. 14. Zhou, J. et al. (2008) Salvicine inactivates beta 1 integrin and inhibits adhesion of MDA-MB-435 cells to fibronectin via reactive oxygen species signaling.Mol Cancer Res. 6: 194-204. 15. Thodeti, C.K. et al. (2003) ADAM12/syndecan-4 signaling promotes beta 1 integrin-dependent cell spreading through protein kinase Calpha and RhoA.J Biol Chem. 278: 9576-84. 16. Lee, H. et al. (2006) A critical role for the membrane-type 1 matrix metalloproteinase in collagen phagocytosis.Mol Biol Cell. 17: 4812-26. 17. Gravelle, S. et al. (2010) Up-regulation of integrin expression in lung adenocarcinoma cells caused by bacterial infection: in vitro study.Innate Immun. 2010 Feb;16(1):14-26. 18. Jović, M. et al. (2007) EHD1 regulates beta1 integrin endosomal transport: effects on focal adhesions, cell spreading and migration.J Cell Sci. 120: 802-14. 19. Newsome, P.N. et al. (2014) Serum from patients with fulminant hepatic failure causes hepatocyte detachment and apoptosis by a beta(1)-integrin pathway.Hepatology. 40: 636-45.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.